Issue link: https://www.e-digitaleditions.com/i/1475629
Inhalation August 2022 31 Integrated DPI development services For 25 years, Lonza Small Molecules has provided integrated dry powder inhaler (DPI) development services to advance molecules. As part of our com- mitment to provide bioavailability enhancement services to global partners, we have announced investments in additional inhalation capacities at our Tampa, US site. Building upon expertise in par- ticle engineering, formulation design and encapsu- lation techniques, the extension provides additional infrastructure to drive efficiency and project delivery for feasibility and early-stage clinical studies. Con- tact us for more information. Lonza Small Molecules US +1 813 286-0404 www.pharma.lonza.com New spray drying capabilities Particle engineering is being used increasingly in drug development, particularly for complex dosage forms such as orally inhaled and nasal drug prod- ucts (OINDPs), where controlled deposition in the respiratory system is key to efficacy. Particle engineer- ing offers multiple options for tailoring particle size to optimize and target delivery to a specific region. It also offers a controlled manufacturing process to build a stable, engineered product, which could pro- vide significant advantages for the formulation of biologics. Intertek has recently invested in spray dry- ing to further our capabilities in the development of respiratory products. Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com DPI development and manufacturing services Experic's experienced team provides customized and scalable filling, packaging and logistics solutions at clinical- and commercial-scale for reservoir and single-dose dry powder inhalation (DPI) devices. From early development and manufacturing for any single- dose unit, to clinical trial supplies and logistics, Experic offers services that can solve dry powder inhaler manufacturing challenges, acceler- ate time to market, and mitigate risk for products with a range of properties, particle sizes, doses and throughput requirements. Experic LLC US: +1 609 537-4040 www.expericservices.com Design, development and manufacture Recipharm has a long history in the design, develop- ment and manufacture of drug products and drug delivery devices, including inhalers and nasal tech- nologies. Product characterization is also part of its core capabilities including analytical method devel- opment, validation and testing services to support all phases of product development. Recipharm uses the latest technologies to generate aerosols suitable for inhalation and uses a variety of methods to analyze particle size including laser diffraction, microscopy, and spray pattern and plume geometry. By develop- ing products with the device and commercial man- ufacture in mind, Recipharm can eliminate hurdles and reduce time to market. Recipharm Sweden: +46 8 602 52 00 www.recipharm.com